Rule of five violations among the FDA-approved small molecule protein kinase inhibitors

Abstract

Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is the target of many drug discovery programs in the pharmaceutical industry. Overall, the US FDA has approved 74 small molecule protein kinase inhibitors, nearly all of which are orally effective. Of the 74 approved drugs, thirty-nine block receptor protein-tyrosine kinases, nineteen target nonreceptor protein-tyrosine kinases, twelve are directed against protein-serine/threonine protein kinases, and four target dual specificity protein kinases. The data indicate that 65 of these medicinals are approved for the management of neoplasms (51 against solid tumors such as breast, colon, and lung cancers, eight against nonsolid tumors such as leukemia, and six against both types of tumors). Nine of the FDA-approved kinase inhibitors form covalent bonds with their target enzymes and they are accordingly classified as TCIs (targeted covalent inhibitors). Medicinal chemists have examined the physicochemical properties of drugs that are orally effective. Lipinski's rule of five (Ro5) is a computational procedure that is used to estimate solubility, membrane permeability, and pharmacological effectiveness in the drug-discovery setting. It relies on four parameters including molecular weight, number of hydrogen bond donors and acceptors, and the Log of the partition coefficient. Other important descriptors include the lipophilic efficiency, the polar surface area, and the number of rotatable bonds and aromatic rings. We tabulated these and other properties of the FDA-approved kinase inhibitors. Of the 74 approved drugs, 30 fail to comply with the rule of five.

Keywords: Alectinib (PubMED CID: 49806720); Crizotinib (PubMED CID: 9033117); Hydrogen-bond; Imatinib (PubMED CID: 123596); Lipinski rule of five; Lipophilic efficiency; Netarsudil (PubMED CID: 66599893); Orally bioavailable; Osimertinib (PubMED CID:71496458); Partition coefficient; Polar surface area; Ruxolitinib (PubMED CID: 25126798); Sunitinib (PubMED CID: 5329102); Tivozanib (PubMED CID: 9911830); Tofacitinib (PubMED CID: 9926791); Vemurafenib (PubMED CID: 42611257).